Claudia Fredolini

Key publications

Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories
Janosch Hauser
Matilda DaleOlof BeckJochen M SchwenkGöran StemmeClaudia Fredolini, Niclas Roxhed
Anal Chem. 2023 Jan 17;95(2):1350-1358. doi: 10.1021/acs.analchem.2c04318. Epub 2022 Dec 22. PMID: 36548393; PMCID: PMC9850402.


Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2.
Roxhed N, Bendes A, Dale M, Mattsson C, Hanke L, Dodig-Crnković T, Christian M, Meineke B, Elsässer S, Andréll J, Havervall S, Thålin C, Eklund C, Dillner J, Beck O, Thomas CE, McInerney G, Hong MG, Murrell B, Fredolini C, Schwenk JM.
Nat Commun. 2021 Jun 17;12(1):3695. doi: 10.1038/s41467-021-23893-4.

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients.
Zeybel M, Altay O, Arif M, Li X, Yang H, Fredolini C, Akyildiz M, Saglam B, Gonenli MG, Ural D, Kim W, Schwenk JM, Zhang C, Shoaie S, Nielsen J, Uhlén M, Borén J, Mardinoglu A.
Mol Syst Biol. 2021 Oct;17(10):e10459. doi: 10.15252/msb.202110459.

Microfluid Device and Method thereof for assays in samples from mammals (on-chip immunoassay)
Inventors: Niclas Roxhed, Bonsens AB, Claudia Fredolini, Janosch Hauser
Patent application number at Swedish Patent and registration office (PRV): 2130266-6

Precise blood proteome profiling in an undiagnosed population with COVID-19. 
Claudia Fredolini, Tea Dodig-Crnković, Annika Bendes, Leo Dahl Matilda Dale, Cecilia Mattsson, Cecilia E Thomas, Olof Beck, Niclas Roxhed and Jochen M Schwenk. (Pre-Print on Medrxiv and under revision ).

Bead-Based Assays for Validating Proteomic Profiles in Body Fluids
Bendes A, Dale M, Mattsson C, Dodig-Crnković T, Iglesias MJ, Schwenk JM, Fredolini C.
Methods Mol Biol. 2021;2344:65-78. doi: 10.1007/978-1-0716-1562-1_5.”

Claudia Fredolini

Research Interests

The Affinity Proteomics Units-Stockholm supports clinical researchers providing cutting edge affinity-based methods for protein quantification in body fluids.

Our equipment and expertise makes us capable to perform protein profiling of large sample cohorts and to contribute to biomarker studies from discovery to verification and validation.

We are part of the Biomarker platform within the European infrastructure for translational medicine (EATRIS).

We host a number of commercial platforms (PEA Olink, Simoa Quanterix, bead-based, Luminex, ecc) that we apply to offer commercial available assay kit upon request. However, we are also engaged in technological development, and we adapt our open platforms to develop novel methods and applications (eg. immunoassays for new candidate biomarkers not available in the market yet, detection of protein-protein interactions, virus particles, patients centric micro-sampling in line with ultra sensitive assays, ecc).

The development of new workflows and methods involves a number of inter-unit and inter-platforms collaboration at Scilifelab.

We collaborate with researchers in the technological fields and with companies to promote the translation of new biomarkers and technologies from the bench into practical applications and marketable products (eg. clinical trials, test of new device prototypes, ecc).


Last updated: 2023-02-23

Content Responsible: David Gotthold(